Condition: B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative · Lymphoblastic Lymphoma · Sponsor: City of Hope Medical Center
This phase II trial tests the safety, side effects, and effectiveness of asparaginase Erwinia chrysanthemi during induction chemotherapy followed by consolidation chemotherapy in treating high-risk adults with newly diagnosed acute lymphoblastic leukemia or lymphoblastic lymphoma. Asparaginase Erwinia chrysanthemi, a type of protein synthesis inhibitor, is a drug that is made up of the enzyme asparaginase, which comes from the bacterium Erwinia chrysanthemi, and is used with other drugs in people who cannot take asparaginase that comes from the bacterium E. coli. Asparaginase Erwinia chrysanthemi breaks down the amino acid asparagine and may stop the growth of cancer cells that need asparagine to grow. It may also kill cancer cells. Induction therapy, consisting of cytarabine, dexamethasone, vincristine, daunorubicin, methotrexate, and rituximab, is the first choice of treatment. Consolidation therapy, consisting of cyclophosphamide, cytarabine, vincristine, mercaptopurine, methotrexate and rituximab, is given after initial therapy to kill any remaining cancer cells. Vincristine is in a class of medications called vinca alkaloids. It works by stopping cancer cells from growing and dividing and may kill them. Methotrexate is in a class of medications called antimetabolites. It is also a type of antifolate. Methotrexate stops cells from using folic acid to make deoxyribonucleic acid (DNA) and may kill cancer cells. Rituximab is a monoclonal antibody. It binds to a protein calle…
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| City of Hope at Phoenix | Phoenix, Arizona, United States | Recruiting |
| City of Hope Medical Center | Duarte, California, United States | Recruiting |
| City of Hope at Irvine Lennar | Irvine, California, United States | Not Yet Recruiting |
| UC San Diego Moores Cancer Center | La Jolla, California, United States | Not Yet Recruiting |
| UCLA / Jonsson Comprehensive Cancer Center | Los Angeles, California, United States | Not Yet Recruiting |
| University of Chicago Comprehensive Cancer Center | Chicago, Illinois, United States | Not Yet Recruiting |
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | Not Yet Recruiting |
| Cleveland Clinic Foundation | Cleveland, Ohio, United States | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06918431